Labcorp Bioanalytical Services
Labcorp Bioanalytical Services is a global leader in nonclinical and clinical bioanalysis and ready to partner with you to help you advance along the drug development continuum.
When Exceptional Science and Trusted Expertise Matter Most
Count on Labcorp Bioanalytical Services’ breadth and depth of scientific expertise to help you along your drug development journey. Across small molecule, large molecule and molecular modality projects, our highly experienced subject matter experts will partner with you to skillfully advance your drug development goals.
Our seven global sites in the U.S., U.K. and Asia offer exceptional science across the discovery, nonclinical and clinical landscape including PK, TK, PD, bioavailability, immunogenicity, bioequivalence, TDM and drug-drug interactions, as well as biodistribution, vector shedding and vector copy number studies for both general and special populations.
With over 40 years of bioanalytical experience and industry thought leadership insights, we can help you advance even your most difficult projects when it matters most.
Please visit our website to learn more: https://biopharma.labcorp.com/services/analytical-services/bioanalytical-services.html
Challenges when designing qPCR/ddPCR assays for cell and gene therapies
Challenges and opportunities for bioanalytical support of new drug modalities
Quantitative approaches for small RNA expression analysis via multi-step RT-qPCR
Panel discussion: bioanalysis for the development and regulatory approval of cell and gene therapies
ICH M10 implementation: global execution and future considerations
Panel discussion: new modalities within bioanalysis
Oiling the oligo engine and running without additives – the continuing journey
Tackling the regulatory uncertainty with qPCR and ddPCR in cell and gene therapy development
Innovative bioanalytical solutions to solve challenges of new therapeutics
Panel discussion: trends in the development of biosimilars
Bringing immune profiling one step closer to clinics with cytometry by time-of-flight (CyTOF)
In the Zone: overcoming hurdles for iChem workflow automation
In the Zone: Research Regulations – China NMPA
In the Zone: bioanalytical matrices – disruption and solutions
Infographic: iChem Workflow – Current advancements in automation and future hurdles
Infographic: Drug applications – the transition from manual to electronic
Infographic: Overcoming the challenges within the bioanalytical matrices supply chain
Infographic: automation considerations and solutions in disruptive times
The hurdles and highlights of immunochemistry workflow automation: an interview with Andrew Hall
Manual to electronic drug application submissions: an interview with Xiaoge Chen
Mitigation strategies for the biological matrix supply chain: an interview with Mark O’Dell
The evolution of iChem workflow automation: a podcast with Andrew Hall
The baseline-disturbing adventures of the ghost-peak busters in mass spook-trometry and beyond
Robert MacNeill: a disturbance in ‘the Force’
Robert MacNeill: the ‘OOPS’ of intent and design
Ask the Experts: the draft ICH M10 guidance – Bioanalysis Zone (bioanalysis-zone.com)
1. First, can you give a brief overview of the ICH M10, its history and where it is at currently?
2. Why is there a need NOW for the ICH M10 guidance and for harmonization efforts?
3. What have been some significant hurdles in developing the ICH M10 guidance?
5. How does the ICH M10 affect bioanalytical outsourcing?
Ask the Experts: utilizing flow cytometry in cell and gene therapies